These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33998869)

  • 1. Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression.
    Wiese BM; Liktor-Busa E; Levine A; Couture SA; Nikas SP; Ji L; Liu Y; Mackie K; Makriyannis A; Largent-Milnes TM; Vanderah TW
    Cannabis Cannabinoid Res; 2021 Oct; 6(5):401-412. PubMed ID: 33998869
    [No Abstract]   [Full Text] [Related]  

  • 2. Brain Penetrant, but not Peripherally Restricted, Synthetic Cannabinoid 1 Receptor Agonists Promote Morphine-Mediated Respiratory Depression.
    Wiese BM; Liktor-Busa E; Couture SA; Nikas SP; Ji L; Liu Y; Makriyannis A; Spigelman I; Vanderah TW; Largent-Milnes TM
    Cannabis Cannabinoid Res; 2022 Oct; 7(5):621-627. PubMed ID: 34935460
    [No Abstract]   [Full Text] [Related]  

  • 3. Cannabinoid 1 and mu-Opioid Receptor Agonists Synergistically Inhibit Abdominal Pain and Lack Side Effects in Mice.
    Yu Y; Tsang QK; Jaramillo-Polanco J; Lomax AE; Vanner SJ; Reed DE
    J Neurosci; 2022 Aug; 42(33):6313-6324. PubMed ID: 35790401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid CB
    Zavala CA; Thomaz AC; Iyer V; Mackie K; Hohmann AG
    Cannabis Cannabinoid Res; 2021 Oct; 6(5):389-400. PubMed ID: 33998863
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.
    Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW
    Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
    Datta U; Kelley LK; Middleton JW; Gilpin NW
    Psychopharmacology (Berl); 2020 Dec; 237(12):3729-3739. PubMed ID: 32857187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
    Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
    Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.
    Yuill MB; Hale DE; Guindon J; Morgan DJ
    Mol Pain; 2017; 13():1744806917728227. PubMed ID: 28879802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cannabinoid CB
    Iyer V; Slivicki RA; Thomaz AC; Crystal JD; Mackie K; Hohmann AG
    Eur J Pharmacol; 2020 Nov; 886():173544. PubMed ID: 32896549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
    Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
    Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure.
    Maguire DR; France CP
    Psychopharmacology (Berl); 2018 Aug; 235(8):2357-2365. PubMed ID: 29860612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Leu/Val
    Llinas Del Torrent C; Raïch I; Gonzalez A; Casajuana-Martin N; Lillo J; Rebassa JB; Ferreiro-Vera C; Sánchez de Medina V; Franco R; Navarro G; Pardo L
    J Chem Inf Model; 2023 Sep; 63(18):5927-5935. PubMed ID: 37644761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca
    Xia KK; Shen JX; Huang ZB; Song HM; Gao M; Chen DJ; Zhang SJ; Wu J
    Acta Pharmacol Sin; 2019 Mar; 40(3):410-417. PubMed ID: 30202013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
    Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
    Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ß-arrestin 2 germline knockout does not attenuate opioid respiratory depression.
    Bachmutsky I; Wei XP; Durand A; Yackle K
    Elife; 2021 May; 10():. PubMed ID: 34002697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowly Signaling G Protein-Biased CB
    Lin X; Dhopeshwarkar AS; Huibregtse M; Mackie K; Hohmann AG
    Mol Pharmacol; 2018 Feb; 93(2):49-62. PubMed ID: 29192123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
    Davis MP
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.